Voyager Therapeutics (NASDAQ:VYGR) Coverage Initiated by Analysts at Wedbush

Investment analysts at Wedbush assumed coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research report issued on Friday. The brokerage set an “outperform” rating and a $11.00 price target on the stock. Wedbush’s price target suggests a potential upside of 90.31% from the stock’s current price.

VYGR has been the topic of several other research reports. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Leerink Partners initiated coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price on the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Finally, StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, November 18th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $17.50.

Voyager Therapeutics Stock Up 1.9 %

VYGR opened at $5.78 on Friday. Voyager Therapeutics has a 52-week low of $5.19 and a 52-week high of $11.72. The company has a market cap of $315.76 million, a P/E ratio of 8.14 and a beta of 0.89. The firm’s 50-day moving average price is $6.50 and its 200-day moving average price is $7.32.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. During the same quarter in the prior year, the company posted ($0.59) earnings per share. On average, research analysts anticipate that Voyager Therapeutics will post -1.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now owns 86,001 shares in the company, valued at approximately $500,525.82. This represents a 6.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Several hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its stake in shares of Voyager Therapeutics by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after buying an additional 4,098 shares during the period. Intech Investment Management LLC acquired a new position in shares of Voyager Therapeutics during the 3rd quarter worth approximately $74,000. SG Americas Securities LLC acquired a new position in shares of Voyager Therapeutics during the 2nd quarter worth approximately $85,000. Victory Capital Management Inc. raised its stake in shares of Voyager Therapeutics by 14.5% during the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after buying an additional 1,630 shares during the period. Finally, Hsbc Holdings PLC acquired a new position in shares of Voyager Therapeutics during the 2nd quarter worth approximately $128,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.